OVERVIEW

2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression is organized by Tarsus CNS.

Target Audience:
The educational design of this activity addresses the needs of US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Credit Designation Statement(s):
Physician Credit Designation
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Nursing Continuing Education:
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes 0.9 pharmacotherapy hours.

Credit Designation:
Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-426-H01-P

Dietician Accreditation Statement:
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.

Program Description:
Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes through a 20 years' duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published data from clinical trials assessing cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists (RAs) show positive affects on the development and progression of DKD.

This virtual symposium will utilize interactive infographics to provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs.

Educational Objectives:
After completing this activity, the participant should be better able to:
• Describe the relationship between T2DM, hypertension, and cardiorenal syndrome
• Review the most current T2DM algorithms and guidelines for the individualized treatment of complex patients, specifically those with DKD
• Summarize the mode of action and effects of GLP-1 RAs and SGLT-2 inhibitors on renal physiology in patients with T2DM and DKD
• Develop management plans for T2DM patients that consider the recently discovered renal effects of SGLT2 inhibitors and GLP-1 RAs.

FACULTY

Matthew Weir

MDInternal Medicine, Nephrology

Lance Sloan

MD, FACE, FASNEndocrinology, Nephrology, Internal Medicine

Robert Daniel Toto

MDNephrology, Internal Medicine

SPECIALITIES

NephrologyEndocrinology, Metabolism and Diabetes

CANCELLATION & REFUND POLICY

This is our canceling policy

Cancellations must be submitted in writing. If you are calling to cancel, for verification we will still require you to send an email to info@brainweek.org with your intent to cancel. You will receive confirmation of your cancellation via email.

We will offer a 100% refund within 72 hours from the time of purchase less $100 credit card processing fee.

After 72 hours, refunds will be less 50%. All refund requests must be made in writing and post marked or tax stamped no later than 90 days before the event.

No refund will be made if the request is made within 90 days of the educational event. Refunds will not be issued to non-show registrants.

Substitutions are always welcome in lieu of cancellation. No transfers to alternate events will be made if the request is submitted within 90 days of the original event.

Persons who register and fail to attend will not receive a refund. BRAINWeek, at its sole discretion, may transfer your registration to an upcoming conference or to a healthcare provider colleague. Cancellation of your conference registration does not automatically cancel your hotel room reservation. Please contact the hotel to cancel your room; penalties may apply.